Leadership

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.

More COVID-19 vaccines are beginning to flow into Africa, as coordination between partner organizations and African governmental agencies improves. However, gaps remain in cold chain storage, information flow on the ground is lagging and vaccine hesitancy persists. Also, pandemic-related economic depression in some African countries is jeopardizing procurement and access to vaccines. 

HashtagHealth builds social media campaigns informed by sophisticated social listening, a focus on specific patient needs and a measurable return on investment for clients. 2021 Rising Leader Brittany Latson, a HashtagHealth co-founder, has leveraged her unique career experiences – at Disney, CVS, and advertising agencies large and small – to create a business that reflects her own values and priorities. 

With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.

Two years into her tenancy as CEO, Bahija Jallal is on the cusp of taking UK biotech Immunocore from a research and development organization to a company with a burgeoning pipeline and a marketed therapy. She talks to In Vivo about validating the platform, an IPO and creating a commercial footprint.

Anthos Therapeutics’ CEO and ex-head of global commercial operations at Novartis Pharma, John Glasspool, says there’s no "automatic premise" that the large promotional launch model is broken. He also outlines how teleconsultation is taking medicine back to its roots and "where it can be" as well, with patients less likely to get white coat syndrome. 

Treating opioid addiction successfully requires an individualized approach, and a lot of money. Executives at addiction treatment centers discuss existing barriers in the recovery pathway and the need to destigmatize addiction and mental health disorders.

Maintaining the positive changes that health care delivery underwent at the height of COVID-19 has been the talk of the health care industries, but will commercial organizations retain their enthusiasm once the pressures of the pandemic abate?

VC Playbook: Pfizer Ventures senior managing partner Barbara Dalton shares insights into how the corporate venture group balances a dual mandate, the trade-offs needed and what success looks like for a CVC.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Lars Christian Wilde, a 2021 In Vivo Rising Leader, is president and co-founder of Compass Pathways, a psychedelic medicines company developing psilocybin for mental health disorders. An entrepreneur who began his career in finance before launching an athletics company, two cooking supply companies and an investment fund, among other achievements, Wilde describes himself as ‘a generalist who surrounds himself with amazing people.’